BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial

, MT Newswires - 12:00 PM ET 3/31/2025 Company News

12:00 PM EDT, 03/31/2025 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Monday acoramidis showed "statistically significant improvements" in clinical outcomes in both variant and wild-type transthyretin amyloid cardiomyopathy, or ATTR-CM, in a phase 3 trial.

The study compared acoramidis with placebo for time to all-cause mortality or first cardiovascular-related hospitalization in both variant and wild-type ATTR-CM, the company said.

Data showed that acoramidis increased serum transthyretin concentrations along with a 59.1% reduction in the risk of mortality or first hospitalization compared with placebo in patients with variant ATTR-CM, and 31.2% risk reduction in patients with wild-type ATTR-CM at month 30, according to the company.

Acoramidis also stabilized TTR levels in both patient groups, demonstrating over 90% stabilization, the company said.

Acoramidis is approved as Attruby in the US and as Beyonttra in the European Union and Japan.

Price: 34.62, Change: -0.49, Percent Change: -1.40

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.